Select Country

MultiHance is the first and only contrast agent indicated for both MRI of the CNS (>2 years) and MRA (adults) in the U.S.1

MultiHance®, the highest relaxivity1 gadolinium-based contrast agent (GBCA) approved for MRI of the CNS, delivers significantly better contrast enhancement in diagnostic imaging of CNS lesions than other tested agents.1-4

MultiHance also provides high relaxivity1, 5-7 and has demonstrated excellent diagnostic performance in MRA8-13 to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.1

MultiHance demonstrates weak and transient interactions with serum proteins that cause slowing in the molecular tumbling dynamics.1

Because of this interaction with serum proteins, MultiHance offers the highest relaxivity of any GBCA approved for CNS MRI available today.6 High relaxivity means a greater ability to shorten proton relaxation times, which increases signal intensity on T1-weighted MR-images.14-16 And greater signal intensity means better contrast enhancement, which may lead to improved visualization.2-4 

Since other extracellular CNS MRI contrast agents do not interact with proteins,17-21 and therefore do not provide strong increases in relaxivity, MultiHance can give you more confidence in your diagnosis for MRI of the CNS (>2 years) and MRA (adults).

Click here to discover the benefits of MultiHance.


REFERENCES: 1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc. July 2012. 2. Pintaske J, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5 and 3 Tesla. Erratum Invest Radiol. 2006;41:213-221. 3. Giesel FL, et al. Influence of Human Serum Albumin on Longitudinal and Transverse Relaxation Rates (R1 and R2) of Magnetic Resonance Contrast Agents. Invest Radiol. 2006;41:222-228. 4. Rohrer M, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724. 5. Achenbach M, Figiel JH, Burbelko M, Heverhagen JT. Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrastenhanced run-off magnetic resonance angiography of the lower extremities. J Magn Reson Imaging. 2010;32(5):1166-1171. 6. Prokop M, Schneider G, Vanzulli A, et al. Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2005;234(2):399-408. 7. Schneider G, Pasowicz M, Vymazal J, et al. Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: Multicenter intraindividual crossover comparison. AJR Am J Roentgenol. 2010;195(2):476-485. 8. Gerretsen SC, le Maire TF, Miller S, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology. 2010;255(3):988-1000. 9. Soulez G, Pasowicz M, Benea G, et al. Renal artery stenosis evaluation: diagnostic performance of gadobenate dimeglumine-enhanced MR angiography – comparison with DSA. Radiology. 2008;247(1):273-285. 10. Thurnher S, Miller S, Schneider G, et al. Diagnostic performance of gadobenate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial. AJR AM J Roentgenol. 2007;189(5):1223-1237. 11. Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR. 2008;29:668-673. 12. Essig M, Hartmann M, Lodemann KP, et al. Comparison of contrast behavior of gadobenatedimeglumine and Gd-DTPA in intra-axial brain tumors. A double-blind randomized intraindividual cross-over study. Applied Radiol. 2003(suppl):92-100. 13. Knopp MV, et al. Assessment of gadobenate dimeglumine for magnetic resonance angiography phase I studies. Invest Radiol. 2002;37:706-715. 14. Magnevist (gadopentetate dimeglumine) injection. Full Prescribing Information. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; March 2012. 15. Gadavist (gadobutrol) injection. Wayne, NJ: Bayer Healthcare Pharmaceuticals; November 2011. 16. ProHance (gadoteridol) injection, 279.3 mg/mL. Full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc.; Sept 2011. 17. Omniscan (gadodiamide) injection (Prescribing Information). Princeton, NJ: GE Healthcare; December 2010. 18. Optimark (gadoversetamide) injection (Prescribing Information). St. Louis, MO: Tyco Healthcare / Mallinkrodt; July 2011.


MultiHance Image pack


See what
you have to gain with the MERIT study.

Read more

Relaxivity Matters

Three independent
studies have proven
that MultiHance’s
highest relaxivity
for CNS MRI matters.

Visit the site


may improve
visualization for MRA

Read more

MULTIHANCE highest Relaxivity

The Highest Relaxivity
Agent for CNS MRI.

Read more

Find Your Rep

Enter your ZIP code in the box below:

MultiHance is a gadolinium-based contrast agent indicated for use in:

  • Magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and children over 2 years of age to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues and
  • Magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease



Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended MultiHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration [See Warnings and Precautions (5.1)]

Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations ranging from mild to severe. The possibility of a reaction should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.

Please consult full Prescribing Information for MultiHance including boxed WARNING contained within this website.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

All trademarks and registered trademarks are the property of their respective owners.

MultiHance is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany) and by Patheon Italia SpA, Ferentino, Italy.